Annual Cash & Cash Equivalents
$386.19 M
+$185.35 M+92.29%
December 31, 2023
Summary
- As of February 7, 2025, AXSM annual cash & cash equivalents is $386.19 million, with the most recent change of +$185.35 million (+92.29%) on December 31, 2023.
- During the last 3 years, AXSM annual cash & cash equivalents has risen by +$202.32 million (+110.03%).
- AXSM annual cash & cash equivalents is now at all-time high.
Performance
AXSM Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$327.34 M
+$11.68 M+3.70%
September 30, 2024
Summary
- As of February 7, 2025, AXSM quarterly cash and cash equivalents is $327.34 million, with the most recent change of +$11.68 million (+3.70%) on September 30, 2024.
- Over the past year, AXSM quarterly cash and cash equivalents has dropped by -$58.85 million (-15.24%).
- AXSM quarterly cash and cash equivalents is now -25.11% below its all-time high of $437.11 million, reached on June 30, 2023.
Performance
AXSM Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AXSM Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +92.3% | -15.2% |
| 3 y3 years | +110.0% | +185.6% |
| 5 y5 years | +2664.7% | +650.1% |
AXSM Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +346.6% | -25.1% | +346.0% |
| 5 y | 5-year | at high | +346.6% | -25.1% | +346.0% |
| alltime | all time | at high | >+9999.0% | -25.1% | >+9999.0% |
Axsome Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $327.34 M(+3.7%) |
| Jun 2024 | - | $315.66 M(-4.8%) |
| Mar 2024 | - | $331.44 M(-14.2%) |
| Dec 2023 | $386.19 M(+92.3%) | $386.19 M(-7.3%) |
| Sep 2023 | - | $416.56 M(-4.7%) |
| Jun 2023 | - | $437.11 M(+77.3%) |
| Mar 2023 | - | $246.51 M(+22.7%) |
| Dec 2022 | $200.84 M(+132.3%) | $200.84 M(-11.7%) |
| Sep 2022 | - | $227.52 M(+210.0%) |
| Jun 2022 | - | $73.39 M(-13.4%) |
| Mar 2022 | - | $84.71 M(-2.0%) |
| Dec 2021 | $86.47 M(-53.0%) | $86.47 M(-24.6%) |
| Sep 2021 | - | $114.62 M(-18.8%) |
| Jun 2021 | - | $141.22 M(-14.2%) |
| Mar 2021 | - | $164.66 M(-10.5%) |
| Dec 2020 | $183.88 M(-16.4%) | $183.88 M(-9.1%) |
| Sep 2020 | - | $202.36 M(+6.1%) |
| Jun 2020 | - | $190.68 M(-3.4%) |
| Mar 2020 | - | $197.31 M(-10.3%) |
| Dec 2019 | $219.97 M | $219.97 M(+404.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $43.64 M(-18.8%) |
| Jun 2019 | - | $53.75 M(+26.1%) |
| Mar 2019 | - | $42.62 M(+205.1%) |
| Dec 2018 | $13.97 M(-58.9%) | $13.97 M(-8.2%) |
| Sep 2018 | - | $15.22 M(-25.2%) |
| Jun 2018 | - | $20.35 M(-23.6%) |
| Mar 2018 | - | $26.63 M(-21.7%) |
| Dec 2017 | $34.02 M(-7.1%) | $34.02 M(+7.4%) |
| Sep 2017 | - | $31.67 M(-16.6%) |
| Jun 2017 | - | $37.99 M(-15.6%) |
| Mar 2017 | - | $45.02 M(+22.9%) |
| Dec 2016 | $36.62 M(-23.8%) | $36.62 M(+8.1%) |
| Sep 2016 | - | $33.89 M(-12.6%) |
| Jun 2016 | - | $38.75 M(-12.1%) |
| Mar 2016 | - | $44.08 M(-8.2%) |
| Dec 2015 | $48.04 M(+1735.0%) | $48.04 M(+939.5%) |
| Sep 2015 | - | $4.62 M(-28.0%) |
| Jun 2015 | - | $6.41 M(+145.0%) |
| Dec 2014 | $2.62 M(+25.4%) | $2.62 M |
| Dec 2013 | $2.09 M | - |
FAQ
- What is Axsome Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Axsome Therapeutics?
- What is Axsome Therapeutics annual cash & cash equivalents year-on-year change?
- What is Axsome Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Axsome Therapeutics?
- What is Axsome Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Axsome Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AXSM is $386.19 M
What is the all time high annual cash & cash equivalents for Axsome Therapeutics?
Axsome Therapeutics all-time high annual cash & cash equivalents is $386.19 M
What is Axsome Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AXSM annual cash & cash equivalents has changed by +$185.35 M (+92.29%)
What is Axsome Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AXSM is $327.34 M
What is the all time high quarterly cash and cash equivalents for Axsome Therapeutics?
Axsome Therapeutics all-time high quarterly cash and cash equivalents is $437.11 M
What is Axsome Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, AXSM quarterly cash and cash equivalents has changed by -$58.85 M (-15.24%)